Statistiche di base
| CIK | 1831097 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to agilon health, inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 (July 29, 2025) agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| August 4, 2025 |
Amended and Restated By-laws of agilon health, inc. Exhibit 3.1 AGILON HEALTH, INC. AMENDED AND RESTATED BY-LAWS Effective as of July 29, 2025 AGILON HEALTH, INC. BY-LAWS Table of Contents Page Section 1.01. Annual Meetings 1 Section 1.02. Special Meetings 1 Section 1.03. Participation in Meetings by Remote Communication 2 Section 1.04. Notice of Meetings; Waiver of Notice 2 Section 1.05. Proxies 3 Section 1.06. Voting Lists 3 Section 1.07. Quorum |
|
| August 4, 2025 |
2Q Earnings Presentation August 2025 Copyright © 2025 agilon health. Confidential internal document containing proprietary information. Do not distribute. 2 Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Se |
|
| August 4, 2025 |
Form of Employee Performance Restricted Stock Unit Agreement – Transformational Goal.†* 1 Exhibit 10.1 [NOTE: BRACKETED PARAGRAPHS REPRESENT ALTERNATE LANGUAGE FOR USE IN AWARDS TO CALIFORNIA EMPLOYEES AND REPLACE THE IMMEDIATE PRIOR PARAGRAPH. BRACKETED BLANK SPACES REPRESENT REDACTED PROPRIETARY INFORMATION] TRANSFORMATIONAL EMPLOYEE AWARD PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT This Transformational Employee Award Performance Restricted Stock Unit Agreement (the “Agreement”), |
|
| August 4, 2025 |
Exhibit 99.2 agilon health Announces Leadership Transition Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full yea |
|
| August 4, 2025 |
Exhibit 99.1 agilon health Reports Second Quarter 2025 Results Total revenues of $1.4 billion in the second quarter 2025 Medicare Advantage membership of 498,000, and total members on the agilon platform of 614,000 as of June 30, 2025 Continued execution on strategic initiatives to enhance financial and clinical data visibility, operational discipline and partnership performance agilon suspends it |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 6, 2025 |
Exhibit 99.1 agilon health Reports First Quarter 2025 Results Total revenues of $1.53 billion in the first quarter 2025 Medicare Advantage membership of 491,000, and total members on the agilon platform of 605,000 as of March 31, 2025 Care patterns in annual wellness and PCP visits consistent with agilon health’s expectations agilon health reaffirms its full year 2025 earnings guidance Westerville |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 6, 2025 |
5.6.2025 First Quarter 2025 Earnings Results Copyright © 2025 agilon health. Confidential internal document containing proprietary information. Do not distribute. 2 Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A o |
|
| April 17, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| February 25, 2025 |
List of Subsidiaries of agilon health, inc. as of December 31, 2024.* Exhibit 21.1 AGILON HEALTH, INC. SUBSIDIARIES OF THE REGISTRANT Legal Name State or Jurisdiction of Incorporation or Organization Agilon Equity PPCP Holdings, LLC Delaware agilon health Catalyst Health Network ACO, Inc. Ohio agilon health Coastal DCE, Inc. South Carolina agilon health Coastal ACO, Inc. Hawaii agilon health Columbus Ohio DCE, Inc. Ohio Agilon Health Holdings, Inc. Delaware Agilon h |
|
| February 25, 2025 |
Exhibit 99.1 agilon health Reports Fourth Quarter and Full Year Fiscal 2024 Results Revenue increased 44% to $1.52 billion in the fourth quarter 2024 Medicare Advantage membership increased 36% to 527,000, and total members on the agilon platform grew to 659,000 as of December 31, 2024 Full year 2025 guidance reflects the positive impact from strategic actions and assumes continued elevated medica |
|
| February 25, 2025 |
February 25, 2025 Fourth Quarter 2024 Earnings Results Copyright © 2024 agilon health 2 Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40 |
|
| February 25, 2025 |
agilon health, inc. Insider Trading Policy.* Exhibit 19.1 agilon health, inc. Insider Trading Policy BACKGROUND/PURPOSE: This policy (this “Policy”) of agilon health, inc. and its subsidiaries (the “Corporation”) concerns trading in the Securities of the Corporation or its affiliates, as well as trading in Securities of other companies. (“Securities” means the common stock or debt securities (such as bonds or debentures) or any other equity |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 5, 2024 |
Form of Indemnification Agreement — Officers Exhibit 10.2 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 2024 by and between agilon health, inc., a Delaware corporation (the “Company”), and [Officer/executive Name] ("Indemnitee"). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, eac |
|
| December 5, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 5, 2024 |
Form of Indemnification Agreement — Directors Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 2024 by and between agilon health, inc., a Delaware corporation (the “Company”), and [Board Director Name] ("Indemnitee"). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, each A |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 19, 2024 |
November 19, 2024 Wolfe Investor Presentation Copyright © 2024 agilon health 2 Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| November 13, 2024 |
AGL / agilon health, inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* agilon health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| November 8, 2024 |
AGL / agilon health, inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* agilon health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| November 8, 2024 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of agilon health, Inc. |
|
| November 7, 2024 |
Exhibit 99.1 agilon health Reports Third Quarter 2024 Results Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medi |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 7, 2024 |
November 7, 2024 Third Quarter 2024 Earnings Results Copyright © 2024 agilon health 2 Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 6, 2024 |
Exhibit 99.1 agilon health Reports Second Quarter 2024 Results Revenue increased 39% to $1.5 billion, Medicare Advantage membership increased 38% to 513,000, and total members on the agilon platform grew 40% to 645,000 Executing targeted action plan and prioritizing profitability First half results reflect retroactive membership adjustments to January 1, 2024 related to agilon’s termination of sel |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| August 6, 2024 |
Form of Employee Performance Restricted Stock Unit Agreement – Stock Appreciation Goal.†* Exhibit 10.2 Employee Performance Restricted Stock Unit Agreement This Employee Performance Restricted Stock Unit Agreement (the “Agreement”), by and between agilon health, inc., a Delaware corporation (the “Company”), and the Employee whose name is set forth on Exhibit A hereto, is being entered into pursuant to the agilon health, inc. 2021 Omnibus Equity Incentive Plan (as amended from time to t |
|
| August 6, 2024 |
Exhibit 10.1 FINAL CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of June , 2024 is entered into by and between Jeffrey Schwaneke (the “Executive”) and agilon health, inc., a Delaware corporation (the “Company”). W I T N E S S E T H: WHEREAS, the Company desires to employ Executive as its Chief Financial Officer, and Executive desires to provide services t |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 5, 2024 |
agilon health Names Jeff Schwaneke New Chief Financial Officer Exhibit 99.1 agilon health Names Jeff Schwaneke New Chief Financial Officer AUSTIN, TX, June 5, 2024 – agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon’s board, will join the Company as chief financial offi |
|
| June 3, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 7, 2024 |
Exhibit 99.1 agilon health Reports First Quarter 2024 Results Revenue increased 52% to $1.6 billion, Medicare Advantage membership increased 43% to 523,000, and total members on the agilon platform grew to 654,000 Continued progress executing performance action plan with focus on driving profitability and enhancing operating efficiency Maintaining full year 2024 guidance for Medical Margin and Adj |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| April 18, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| February 27, 2024 |
4Q Earnings Presentation February 2024 Copyright © 2023 agilon health. Confidential internal document containing proprietary information. Do not distribute. 2 Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the |
|
| February 27, 2024 |
List of Subsidiaries of agilon health as of December 31, 2023.* Exhibit 21.1 AGILON HEALTH, INC. SUBSIDIARIES OF THE REGISTRANT Legal Name State or Jurisdiction of Incorporation or Organization Agilon Equity PPCP Holdings, LLC Delaware agilon health Catalyst Health Network ACO, Inc. Ohio agilon health Coastal DCE, Inc. South Carolina agilon health Coastal ACO, Inc. Hawaii agilon health Columbus Ohio DCE, Inc. Ohio Agilon Health Holdings, Inc. Delaware Agilon h |
|
| February 27, 2024 |
agilon health, inc. Policy Regarding Recovery of Erroneously Awarded Compensation. Exhibit 97.1 agilon health, inc. Clawback Policy Adopted November 14, 2023 The Board of Directors (the “Board”) of agilon health, inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Clawback Policy (the “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40 |
|
| February 27, 2024 |
Exhibit 99.1 agilon health Reports Fourth Quarter 2023 Results Revenue increased 72% to $1.06 billion in the fourth quarter 2023, Medicare Advantage membership increased 68% to 388,400, and total members on the agilon platform grew to 477,700 as of December 31, 2023 2023 performance impacted by acceleration in medical costs due to macro dynamics, revised 2024 guidance assumes continuation of highe |
|
| February 13, 2024 |
AGL / agilon health, inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0204-agilonhealthinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: agilon health Inc Title of Class of Securities: Common Stock CUSIP Number: 00857U107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to whic |
|
| February 9, 2024 |
AGL / agilon health, inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* agilon health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 8, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.1 2 d658066dex991.htm EX-99.1 Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 8, 2024 |
AGL / agilon health, inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* agilon health, inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 8, 2024 |
agilon health Announces Chief Medical Officer Transition Exhibit 99.1 agilon health Announces Chief Medical Officer Transition AUSTIN, T.X., February 8, 2024 – agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to the company and will transition from his role as chief medical officer (CMO) ef |
|
| February 8, 2024 |
AGL / agilon health, inc. / CD&R Vector Holdings, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d658066dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* agilon health, inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00857U 10 7 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| January 5, 2024 |
agl-8kx01052024xex992 Guidance Update January 2024 Copyright © 2023 agilon health. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 5, 2024 |
agilon health Announces Tim Bensley to Retire as CFO Exhibit 99.1 agilon health Announces Tim Bensley to Retire as CFO AUSTIN, TX, JANUARY 5, 2024 – agilon health, Inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that Timothy Bensley has informed the company of his intent to retire from his position as Chief Financial Officer (CFO) during 2024, which agilon expects to take place |
|
| January 5, 2024 |
Exhibit 99.1 agilon health Provides 2023 Guidance Update, Initial 2024 View Revised 2023 expectations and early outlook for 2024 reflect higher medical and non-medical costs Company is taking targeted actions to improve visibility, balance risk-sharing, and improve predictability of results in 2024 and over the long term agilon health to host conference call at 8:00 AM Eastern Time today AUSTIN, T |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 14, 2023 |
agl-2023investorconferen Wolfe Healthcare Conference November 2023 Copyright © 2023 agilon health. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| November 2, 2023 |
Exhibit 99.1 agilon health Reports Third Quarter 2023 Results Revenue increased 75% to $1.22 billion, Medicare Advantage membership increased 58% to 420,300, and total members live on the agilon platform grew to 508,000 Strong performance across core partner markets supported by membership growth and profitability gains in Medicare Advantage and ACO REACH Sale of MDX Hawaii enables agilon to focus |
|
| November 2, 2023 |
Supplemental Financial Information (unaudited) 11.2.2023 Supplemental Financial Information Dollars In Thousands (unaudited) Key Financial and Operating Metrics, Excluding MDX Hawaii (Non-GAAP) On October 31, 2023, we completed the disposition of our MDX Hawaii operations. To facilitate investors’ review and understanding of agilon health, inc.’s operating results, Medicare Advantage Members, Aver |
|
| September 8, 2023 |
AGL / Agilon Health Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* agilon health, inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) August 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 (August 11, 2023) agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporatio |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 3, 2023 |
agilonsecondamendmenttoc EXECUTION VERSION SECOND AMENDMENT TO CREDIT AGREEMENT SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of May 25, 2023 (this “Second Amendment”), to the Credit Agreement referred to below, between agilon health, inc. |
|
| August 3, 2023 |
Exhibit 99.1 agilon health Reports Second Quarter 2023 Results Revenue increased 71% to $1.15 billion, Medicare Advantage membership increased 57% to 408,900, and total members live on the agilon platform grew to 495,900 Durability of agilon partnership model driving continued gains in profitability across Medicare Advantage and ACO REACH, inclusive of higher membership Updating outlook for 2023 a |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| June 26, 2023 |
Exhibit 99.1 agilon health Names Silvana Battaglia to Board of Directors Longtime Human Resources Executive Brings Significant Business Leadership Experience to Role as Independent Member of agilon’s Board Austin, TX, June 26, 2023- agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that Silvana Battaglia has been |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 agilon health, inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 (May 15, 2023) agilon health, inc. (Exact name of registrant as specified in its charter) Delaware 001-40332 37-1915147 (State or other jurisdiction of incorporation) (Co |
|
| May 18, 2023 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION agilon health, inc. 86,884,353 Shares of Common Stock Underwriting Agreement May 15, 2023 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC BofA Securities, Inc. As Representatives of the several Underwriters named in Schedule I hereto, c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman Sachs & Co. LLC 200 West Street New York, |
|
| May 17, 2023 |
86,884,353 Shares agilon health, inc. Common Stock Form 424(b)(7) Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. |
|
| May 16, 2023 |
FWP Free Writing Prospectus Dated May 15, 2023 Filed Pursuant to Rule 433 Registration Statement No. |
|
| May 15, 2023 |
SUBJECT TO COMPLETION, DATED MAY 15, 2023 70,000,000 Shares agilon health, inc. Common Stock Form 424(b)(7) Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. |
|
| May 15, 2023 |
As filed with the U.S. Securities and Exchange Commission on May 15, 2023 Form S-3ASR Table of Contents As filed with the U.S. Securities and Exchange Commission on May 15, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 agilon health, inc. (Exact name of registrant as specified in its charter) Delaware 3699 37-1915147 (State or other jurisdiction of incor |
|
| May 15, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) agilon health, inc. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the |
|
| May 9, 2023 |
Exhibit 99.1 agilon health Reports First Quarter 2023 Results Revenue increased 74% to $1.14 billion and Medicare Advantage membership increased 61% to 402,200 Total members live on the agilon platform grew to 490,900, including 402,200 Medicare Advantage members and 88,700 ACO REACH beneficiaries Continued gains in profitability driven by strong performance across partner markets, inclusive of hi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40332 agilon he |
|
| May 1, 2023 |
CORRESP May 1, 2023 VIA EDGAR Kristin Lochhead U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-7010 Re: agilon health, inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 1, 2023 File No. 001-40332 Dear Ms. Lochhead: This letter sets forth the responses of agilon heal |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitte |
|
| April 3, 2023 |
April 3, 2023 VIA EDGAR Kristin Lochhead U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-7010 Re: agilon health, inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 1, 2023 File No. 001-40332 Dear Ms. Lochhead: This letter sets forth the responses of agilon health, in |
|
| March 10, 2023 |
AGL / Agilon Health Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Agilon Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) February 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2023 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40 |
|
| March 1, 2023 |
List of Subsidiaries of agilon health as of February 15, 2023.* Exhibit 21.1 AGILON HEALTH, INC. SUBSIDIARIES OF THE REGISTRANT Legal Name State or Jurisdiction of Incorporation or Organization Agilon Equity PPCP Holdings, LLC Delaware agilon health Catalyst Health Network ACO, Inc. Ohio agilon health Coastal DCE, Inc. South Carolina agilon health Coastal DCE Inc. Hawaii agilon health Columbus Ohio DCE, Inc. Ohio Agilon Health Holdings, Inc. Delaware Agilon he |
|
| March 1, 2023 |
Exhibit 10.10 Confidential EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement"), dated as of March 5, 2017, is entered into by and between Veeral Desai (the "Executive"), Agilon Health Holdings, Inc., a Delaware corporation ("Parent"), and agilon health, inc., a Delaware corporation and wholly-owned subsidiary of Parent (the "Company"). W I T N E S S E T H: WHEREAS, Parent and the Com |
|
| March 1, 2023 |
Exhibit 99.1 agilon health Reports Fourth Quarter and Fiscal Year 2022 Results Revenue increased 49% to $690 million, Medicare Advantage membership increased 45% to 269,500, and Medical Margin increased 93% to $61 million during the fourth quarter Guidance for 2023 includes significant gains in Adjusted EBITDA to $75 million to $90 million while maintaining strong revenue and membership growth1 Cl |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 13, 2023 |
AGL / agilon health, inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Agilon Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2023 |
AGL / agilon health, inc. / CD&R Vector Holdings, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d430831dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* agilon health, inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00857U 10 7 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 10, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.1 2 d430831dex991.htm EX-99.1 Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this |
|
| February 6, 2023 |
AGL / agilon health, inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Agilon Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40332 agilo |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 3, 2022 |
Exhibit 99.1 agilon health Reports Third Quarter 2022 Results Revenue increased 52% to $695 million, Medicare Advantage membership increased 45% to 266,600, and Medical Margin increased 74% to $76 million Total members live on the agilon platform grew to 356,000, including 266,600 Medicare Advantage members and 89,400 Direct Contracting beneficiaries Continued gains in Medicare Advantage profitabi |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40332 agilon hea |
|
| August 4, 2022 |
Exhibit 99.1 agilon health Reports Second Quarter 2022 Results Revenue increased 45% and Medicare Advantage membership grew 44% year-to-date Total members live on the agilon platform grew to 351,700, including 261,200 Medicare Advantage members and 90,500 Direct Contracting beneficiaries Medical Margin increased 49% to $82 million during the second quarter, with profitability gains driven by agilo |
|
| May 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 5, 2022 |
Exhibit 10.4 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This SEPARATION AGREEMENT AND GENERAL RELEASE (the ?Agreement?), dated as of March 18 2022, is entered into by and among agilon health management, inc. (f/k/a agilon health, inc.) (the ?Company? and together with its parent, agilon health, inc. and their respective subsidiaries and affiliates, the ?Company Group?), and the undersigned |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 5, 2022 |
Exhibit 99.1 agilon health Reports First Quarter 2022 Results Revenue growth of 58%, driven by 51% growth in Medicare Advantage membership Total members live on the agilon platform grew to 342,000, including 250,000 Medicare Advantage members and 92,000 Direct Contracting beneficiaries Medical Margin increased 66%, reflecting agilon?s aligned partnership model driving positive results across diver |
|
| May 5, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of April 4, 2022, is entered into by and between Benjamin Shaker (the ?Executive?) and agilon health, inc., a Delaware corporation (the ?Company?). W I T N E S S E T H: WHEREAS, Executive is currently employed as Chief Markets Officer of the Company; WHEREAS, in recognition of Executive?s role with the Company |
|
| May 5, 2022 |
Exhibit 10.3 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This SEPARATION AGREEMENT AND GENERAL RELEASE (the ?Agreement?), dated as of February 10, 2022, is entered into by and among agilon health management, inc. (f/k/a agilon health, inc.) (the ?Company? and, together with its parent, agilon health, inc., and their respective subsidiaries and affiliates, the ?Company Group?), and the under |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40332 agilon he |
|
| May 5, 2022 |
Exhibit 10.2 CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of 03/31/2022 is entered into by and between Girish Venkatachaliah (the ?Executive?) and agilon health, inc., a Delaware corporation (the ?Company?). W I T N E S S E T H: WHEREAS, Executive is currently employed as Chief Technology Officer of the Company; WHEREAS, in recognition of Executive?s rol |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION DEFA14A 1 ny20002099x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm |
|
| April 11, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant?? ? ? Filed by a Party other than the Registrant??? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission O |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 3, 2022 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common stock, par value $0.01 per share, of agilon health, inc. (?us,? ?we,? ?our,? and the ?Company?), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF COM |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40 |
|
| March 3, 2022 |
Exhibit 99.1 agilon health Reports Fourth Quarter and Fiscal Year 2021 Results Revenue growth of 44% for the fourth quarter and 50% for fiscal year 2021 Total members live on the agilon platform grew 82% to 238,000, driven by 42% growth in Medicare Advantage and contribution from Direct Contracting Guidance for 2022 includes significant gains in Adjusted EBITDA while maintaining strong revenue gro |
|
| March 3, 2022 |
List of Subsidiaries of agilon health as of February 15, 2022.* Exhibit 21.1 AGILON HEALTH, INC. SUBSIDIARIES OF THE REGISTRANT Legal Name State or Jurisdiction of Incorporation or Organization agilon health Coastal DCE, Inc. South Carolina agilon health Coastal DCE Inc. Hawaii agilon health Columbus Ohio DCE, Inc. Ohio Agilon Health Holdings, Inc. Delaware agilon health of California, Inc. Delaware agilon health management, inc. Delaware Agilon Health India P |
|
| February 14, 2022 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.1 Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached. Each o |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 14, 2022 |
AGL / agilon health, inc. / CD&R Vector Holdings, L.P. - SC 13G Passive Investment SC 13G 1 d301975dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* agilon health, inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00857U 10 7 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 11, 2022 |
AGL / agilon health, inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Agilon Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00857U107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 04, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 02, 2021 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40332 agilo |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 28, 2021 |
Exhibit 99.1 agilon health Reports Third Quarter 2021 Results Revenue growth of 47%, driven by 43% growth in Medicare Advantage membership Total membership growth of 83%, including Medicare Advantage and Direct Contracting Raised 2021 guidance for membership, revenue, and Adjusted EBITDA 2022 total membership expected to grow 45%+, with 40%+ growth in Medicare Advantage LONG BEACH, Calif., October |
|
| September 13, 2021 |
17,000,000 Shares agilon health, inc. Common Stock 424B4 1 d189358d424b4.htm 424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-259159 17,000,000 Shares agilon health, inc. Common Stock The selling stockholders identified in this prospectus are offering 17,000,000 shares of common stock of agilon health, inc. (“agilon health”). We will not receive any of the proceeds of the sale of our common stock being sold in this off |
|
| September 7, 2021 |
As filed with the Securities and Exchange Commission on September 7, 2021 Form S-1/A Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on September 7, 2021 Registration No. |
|
| September 7, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 agilon health, inc. [?] Shares of Common Stock Underwriting Agreement September [?], 2021 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC BofA Securities, Inc. As Representatives of the several Underwriters named in Schedule I hereto, c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 BofA Secur |
|
| August 30, 2021 |
List of Subsidiaries of agilon health as of August 1, 2021. Exhibit 21.1 AGILON HEALTH, INC. SUBSIDIARIES OF THE REGISTRANT Legal Name State or Jurisdiction of Incorporation or Organization agilon health Coastal DCE, Inc. South Carolina Agilon Health Holdings, Inc. Delaware agilon health of California, Inc. Delaware agilon health management, inc. Delaware Agilon Health India Private Limited India Agilon Heath Intermediate Holdings, Inc. Delaware Agilon MSO |
|
| August 30, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on August 30, 2021 Registration No. |
|
| August 4, 2021 |
Quarter Ending September 30, 2021 Exhibit 99.1 agilon health Reports Second Quarter 2021 Results LONG BEACH, Calif. ? August 4, 2021 ? agilon health, inc. (NYSE: AGL), the company transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients, announced results for the second quarter ended June 30, 2021. Second Quarter 2021 Results: ? Total revenue of $499 million increas |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40332 agilon hea |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2021 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 26, 2021 |
Table of Contents Index to Financial Statements Confidential Treatment Requested by agilon health, inc. |
|
| July 26, 2021 |
Confidential Treatment Requested by agilon health, inc. Pursuant to 17 C.F.R. Section 200.83 Confidential Treatment Requested by agilon health, inc. Pursuant to 17 C.F.R. Section 200.83 Exhibit 21.1 AGILON HEALTH, INC. SUBSIDIARIES OF THE REGISTRANT Legal Name State or Jurisdiction of Incorporation or Organization Agilon Health Holdings, Inc. Delaware agilon health of California, Inc. Delaware agilon health management, inc. Delaware Agilon Health India Private Limited India Agilon Heath I |
|
| July 12, 2021 |
agilon health Names Karen McLoughlin to its Board of Directors LONG BEACH, Calif. ? July 12, 2021 ? agilon health, inc. (NYSE: AGL), the company transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients, has named Karen McLoughlin to its board of directors. McLoughlin is the former chief financial officer of Cognizant Technology Solu |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 09, 2021 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 26, 2021 |
Exhibit 99.1 agilon health Reports First Quarter 2021 Results LONG BEACH, Calif. ? May 26, 2021 ? agilon health, inc. (NYSE: AGL), the company transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients, announced results for the first quarter ended March 31, 2021. First Quarter 2021 Results: ? Total revenue of $413 million increased 4 |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40332 agilon he |
|
| May 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 agilon health, inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40332 37-1915147 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 19, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AGILON HEALTH, INC. agilon health, inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is agilon health, inc. 2. The original Certificate of Incorporation of the Corporation was filed for Agilon Health Topco, Inc. with the |
|
| April 19, 2021 |
Exhibit 10.3 EXECUTION VERSION TERMINATION AGREEMENT This TERMINATION AGREEMENT (this ?Agreement?) is entered as of April 16, 2021, by and between Agilon Health Holdings, Inc. (f/k/a CD&R Vector Topco, Inc.), a Delaware corporation (the ?Company?), Primary Provider Management Co., Inc., a California corporation (?Opco?) and Clayton, Dubilier & Rice, LLC, a Delaware limited liability company (?CD&R |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 (April 14, 2021) agilon health, inc. (Exact name of registrant as specified in its charter) Delaware 001-40332 37-1915147 (State or other jurisdiction of incorporation) |
|
| April 19, 2021 |
Exhibit 3.2 AGILON HEALTH, INC. AMENDED AND RESTATED BY-LAWS Effective as of April 16, 2021 AGILON HEALTH, INC. BY-LAWS Table of Contents Page ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1.01. Annual Meetings 1 Section 1.02. Special Meetings 1 Section 1.03. Participation in Meetings by Remote Communication 1 Section 1.04. Notice of Meetings; Waiver of Notice 2 Section 1.05. Proxies 3 Section 1.06 |
|
| April 19, 2021 |
EX-99.1 Exhibit 99.1 agilon health Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares LONG BEACH, Calif. – April 19, 2021 – agilon health, inc. (NYSE: AGL), which partners with primary care physicians to unlock value-based healthcare delivery, announced the closing of its initial public offering of 53,590,000 shares of its common st |
|
| April 19, 2021 |
Exhibit 10.2 STOCKHOLDERS AGREEMENT of AGILON HEALTH, INC. Dated as of April 16, 2021 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 1.1 Certain Defined Terms 1 1.2 Other Definitional Provisions 4 ARTICLE II CORPORATE GOVERNANCE 5 2.1 Board Representation 5 2.2 Available Financial Information 7 2.3 Other Information 8 2.4 Access 9 2.5 Termination of Rights 9 ARTICLE III MISCELLANEOUS 9 3.1 Confide |
|
| April 19, 2021 |
Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT of AGILON HEALTH, INC. Dated as of April 16, 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Incidental Registrations 5 (a) Right to Include Registrable Securities 5 (b) Priority in Incidental Registrations 6 3. Registration on Request 6 (a) Request by the Demand Party 6 (b) Priority on Demand Registration 7 (c) Cancellation of a Demand Registration 8 (d) |
|
| April 16, 2021 |
46,600,000 Shares agilon health, inc. Common Stock Table of Contents Index to Financial Statements Filed pursuant to Rule 424(b)(4) Registration No. |
|
| April 14, 2021 |
Exhibit 10.6 Form of Director Restricted Stock Unit Agreement This Director Restricted Stock Unit Agreement (the ?Agreement?), by and between agilon health, inc., a Delaware corporation (the ?Company?), and the Director whose name is set forth on Exhibit A hereto, is being entered into pursuant to the agilon health, inc. 2021 Omnibus Equity Incentive Plan (the ?Plan?) and is dated as of the date i |
|
| April 14, 2021 |
Exhibit 10.3 Form of Employee Restricted Stock Unit Agreement This Employee Restricted Stock Unit Agreement (the ?Agreement?), by and between agilon health, inc., a Delaware corporation (the ?Company?), and the Employee whose name is set forth on Exhibit A hereto, is being entered into pursuant to the agilon health, inc. 2021 Omnibus Equity Incentive Plan (the ?Plan?) and is dated as of the date i |
|
| April 14, 2021 |
Exhibit 10.5 Form of Employee Stock Option Agreement This Employee Stock Option Agreement (the ?Agreement?), by and between agilon health, inc., a Delaware corporation (the ?Company?), and the Employee whose name is set forth on Exhibit A hereto, is being entered into pursuant to the agilon health, inc. 2021 Omnibus Equity Incentive Plan (the ?Plan?) and is dated as of the date it is accepted and |
|
| April 14, 2021 |
Exhibit 10.1 AGILON HEALTH, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN ARTICLE I PURPOSES This agilon health, inc. 2021 Omnibus Equity Incentive Plan, as may be amended from time to time (the ?Plan?), has the following purposes: (1) To further the growth, development and financial success of agilon health, inc. (the ?Company?) and the Subsidiaries (as defined herein), by providing additional incentiv |
|
| April 14, 2021 |
Exhibit 10.2 AGILON HEALTH, INC. EMPLOYEE STOCK PURCHASE PLAN Article I Purpose The purpose of the agilon health, inc. Employee Stock Purchase Plan (the ?Plan?) is to provide eligible Employees of the Company and its Designated Subsidiaries with an opportunity to purchase shares of Common Stock of the Company through payroll deductions. The Plan is intended to qualify as an ?employee stock purchas |
|
| April 14, 2021 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 agilon health, inc. (Exact name of registrant as specified in its charter) Delaware 37-1915147 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 1 World Trade Center, Suite 2000 Long Beach |
|
| April 14, 2021 |
EX-10.4 6 d173455dex104.htm EX-10.4 Exhibit 10.4 Form of Employee Performance Restricted Stock Unit Agreement This Employee Performance Restricted Stock Unit Agreement (the “Agreement”), by and between agilon health, inc., a Delaware corporation (the “Company”), and the Employee whose name is set forth on Exhibit A hereto, is being entered into pursuant to the agilon health, inc. 2021 Omnibus Equi |
|
| April 14, 2021 |
8-A12B 1 d167645d8a12b.htm FORM 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PUSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 agilon health, inc. (Exact name of registrant as specified in its charter) Delaware 37-1915147 (State or other jurisdiction of incorporation or organization) ( |
|
| April 12, 2021 |
agilon health, inc. 1 World Trade Center, Suite 2000 Long Beach, CA 90831 agilon health, inc. 1 World Trade Center, Suite 2000 Long Beach, CA 90831 April 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Attention: Deanna Virginio Re: agilon health, inc. Registration Statement on Form S-1 (File No. 333-254435) Request for Acceleration of Effective Date Dear Ms. Virginio: Pursuant to |
|
| April 12, 2021 |
April 12, 2021 BY EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Deanna Virginio Joe McCann Lynn Dicker Kristin Lochhead Re: agilon health, inc. Registration Statement Filed on Form S-1 File No. 333-254435 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as a |
|
| April 7, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 agilon health, inc. [?] Shares of Common Stock Underwriting Agreement [?], 2021 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC BofA Securities, Inc. As Representatives of the several Underwriters named in Schedule I hereto, c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 BofA Securities, Inc |
|
| April 7, 2021 |
agilon health Executive Annual Bonus Plan EX-10.21 11 d10763dex1021.htm EX-10.21 Exhibit 10.21 AGILON HEALTH, INC. EXECUTIVE ANNUAL BONUS PLAN I. Purposes The purposes of the agilon health, inc. Executive Annual Bonus Plan (the “Plan”), are to retain and motivate certain executive officers of the Company or any of its Subsidiaries who have been designated by the Committee (as defined below) to participate in the Plan by providing them wit |
|
| April 7, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AGILON HEALTH, INC. agilon health, inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is agilon health, inc. 2. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the Stat |
|
| April 7, 2021 |
Exhibit 3.2 AGILON HEALTH, INC. AMENDED AND RESTATED BY-LAWS Effective as of [●], 2021 AGILON HEALTH, INC. BY-LAWS Table of Contents Page ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1.01. Annual Meetings 1 Section 1.02. Special Meetings 1 Section 1.03. Participation in Meetings by Remote Communication 1 Section 1.04. Notice of Meetings; Waiver of Notice 2 Section 1.05. Proxies 3 Section 1.06. Vot |
|
| April 7, 2021 |
Form of agilon health Employee Stock Purchase Plan Exhibit 10.23 AGILON HEALTH, INC. EMPLOYEE STOCK PURCHASE PLAN Article I Purpose The purpose of the agilon health, inc. Employee Stock Purchase Plan (the “Plan”) is to provide eligible Employees of the Company and its Designated Subsidiaries with an opportunity to purchase shares of Common Stock of the Company through payroll deductions. The Plan is intended to qualify as an “employee stock purcha |
|
| April 7, 2021 |
Form of Stockholders Agreement. EX-10.12 8 d10763dex1012.htm EX-10.12 Exhibit 10.12 STOCKHOLDERS AGREEMENT of AGILON HEALTH, INC. Dated as of [•], 2021 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 1.1 Certain Defined Terms 1 1.2 Other Definitional Provisions 4 ARTICLE II CORPORATE GOVERNANCE 5 2.1 Board Representation 5 2.2 Available Financial Information 7 2.3 Other Information 8 2.4 Access 9 2.5 Termination of Rights 9 ARTIC |
|
| April 7, 2021 |
Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. |
|
| April 7, 2021 |
Form of Registration Rights Agreement, by and between agilon health and CD&R Vector Holdings, L.P. Exhibit 10.14 REGISTRATION RIGHTS AGREEMENT of AGILON HEALTH, INC. Dated as of [?], 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Incidental Registrations 5 (a) Right to Include Registrable Securities 5 (b) Priority in Incidental Registrations 6 3. Registration on Request 6 (a) Request by the Demand Party 6 (b) Priority on Demand Registration 7 (c) Cancellation of a Demand Registration 8 (d) Lim |
|
| April 7, 2021 |
Form of agilon health 2021 Omnibus Equity Incentive Plan EX-10.22 12 d10763dex1022.htm EX-10.22 Exhibit 10.22 AGILON HEALTH, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN ARTICLE I PURPOSES This agilon health, inc. 2021 Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), has the following purposes: (1) To further the growth, development and financial success of agilon health, inc. (the “Company”) and the Subsidiaries (as defined h |
|
| April 7, 2021 |
Form of Consulting Agreement Termination Agreement. Exhibit 10.11 EXECUTION VERSION TERMINATION AGREEMENT This TERMINATION AGREEMENT (this ?Agreement?) is entered as of [?], 2021, by and between Agilon Health Holdings, Inc. (f/k/a CD&R Vector Topco, Inc.), a Delaware corporation (the ?Company?), Primary Provider Management Co., Inc., a California corporation (?Opco?) and Clayton, Dubilier & Rice, LLC, a Delaware limited liability company (?CD&R Man |
|
| April 7, 2021 |
Form of Employee Stock Option Agreement (Base and Upside Options) EX-10.20 10 d10763dex1020.htm EX-10.20 Exhibit 10.20 Confidential agilon health, inc. Employee Stock Option Agreement (Base and Upside Options) This Employee Stock Option Agreement, dated as of , 202 , between agilon health, inc., a Delaware corporation, and the Employee whose name appears on the signature page hereof, is being entered into pursuant to, and is subject to the terms of, the Amended |
|
| April 7, 2021 |
Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PO par value $0.01 MR ADD ADD ADD ADD 432 1 A BOX DESIGNATION SAMPLE Certificate Shares 505006, Number * * 000000 ****************** (IF * * * 000000 ***************** ANY) ZQ00000000 **** 000000 **************** Louisville, agilon hea lth, inc. ***** 000000 *************** KY ****** 000000 ************** INC |
|
| April 5, 2021 |
CORRESP 1 filename1.htm April 5, 2021 Deanna Virginio U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: agilon health, inc. Registration Statement on Form S-1 Filed March 18, 2021 File No. 333-254435 Dear Ms. Virginio: This letter sets forth the responses of agilon health, inc. (the “Registrant”) to th |
|
| April 2, 2021 |
Confidential Treatment Requested by agilon health, inc. Under 17 C.F.R. ? 200.83 CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE OMITTED PORTIONS, WHICH HAVE BEEN REPLACED WITH THE FOLLOWING PLACEHOLDER ?[***]? IN THE LETTER FILED VIA EDGAR. April 1, 2021 VIA EDGAR AND SECURE FILE TRANS |
|
| March 18, 2021 |
EX-10.7 10 d10763dex107.htm EX-10.7 Exhibit 10.7 Confidential AMENDED AND RESTATED AGILON HEALTH TOPCO, INC. STOCK INCENTIVE PLAN Article I Purpose This stock incentive plan of Agilon Health Topco, Inc. has been established to foster and promote its and the Subsidiaries’ long-term financial success. This Plan succeeds and replaces the Agilon Health Holdings, Inc. Stock Incentive Plan (the “Former |
|
| March 18, 2021 |
Exhibit 10.15 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), is made as of the 7th day of November, 2018, by and among Agilon Health Topco, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?, acting by and through one of Morgan St |
|
| March 18, 2021 |
Exhibit 10.17 EXECUTION VERSION INVESTMENT AGREEMENT dated as of November 7, 2018 by and among AGILON HEALTH TOPCO, INC. as the Company and EACH ENTITY LISTED ON EXHIBIT A HERETO as a Purchaser TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1.1 Definitions 1 ARTICLE II SALE AND ISSUANCE OF SHARES 2.1 Sale and Issuance of Shares 7 2.2 Closing 7 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPAN |
|
| March 18, 2021 |
Exhibit 10.19 EXECUTION VERSION INVESTMENT AGREEMENT dated as of March 4, 2020 by and among AGILON HEALTH TOPCO, INC. as the Company and EACH ENTITY LISTED ON EXHIBIT A HERETO as a Purchaser TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1.1 Definitions 1 ARTICLE II SALE AND ISSUANCE OF SHARES 2.1 Sale and Issuance of Shares 10 2.2 Closing 10 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY |
|
| March 18, 2021 |
Exhibit 10.17.1 Execution Version FIRST AMENDMENT TO INVESTMENT AGREEMENT This First Amendment, dated as of October 21, 2020 (this ?Amendment?), to the Investment Agreement (as defined below) is entered into by and among Agilon Health Topco, Inc., a Delaware corporation (the ?Company?), and each entity listed on Exhibit A attached hereto, (each, a ?Purchaser? and collectively, the ?Purchasers?), a |
|
| March 18, 2021 |
List of Subsidiaries of agilon health as of March 1, 2021. Exhibit 21.1 AGILON HEALTH, INC. SUBSIDIARIES OF THE REGISTRANT Legal Name State or Jurisdiction of Incorporation or Organization Agilon Health Holdings, Inc. Delaware agilon health of California, Inc. Delaware agilon health management, inc. Delaware Agilon Heath Intermediate Holdings, Inc. Delaware Agilon MSO Hawaii, Inc. Hawaii Agilon New York Holdco, Inc. New York Arkansas Agilon Holdco, Inc. A |
|
| March 18, 2021 |
Exhibit 10.1.1 EXECUTION VERSION FIRST AMENDMENT TO CREDIT AGREEMENT FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of March 1, 2021 (this ?First Amendment?), to the Credit Agreement referred to below, between agilon health, inc., a Delaware corporation (the ?Borrower?) and JPMorgan Chase Bank, N.A., as Administrative Agent (the ?Administrative Agent?). RECITALS WHEREAS, the Borrower, Agilon Health |
|
| March 18, 2021 |
Exhibit 10.18 EXECUTION VERSION INVESTMENT AGREEMENT dated as of January 4, 2019 by and among AGILON HEALTH TOPCO, INC. as the Company and EACH ENTITY LISTED ON EXHIBIT A HERETO as a Purchaser TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1.1 Definitions 1 ARTICLE II SALE AND ISSUANCE OF SHARES 2.1 Sale and Issuance of Shares 7 2.2 Closing 7 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY |
|
| March 18, 2021 |
Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on March 18, 2021 Registration No. |
|
| March 18, 2021 |
Exhibit 10.13.4 EXECUTION VERSION FOURTH AMENDMENT TO AMENDED AND RESTATED STOCKHOLDERS? AGREEMENT This Fourth Amendment to the Amended and Restated Stockholders? Agreement, dated as of January 30, 2020 (this ?Amendment?), is entered by and between Agilon Health Topco, Inc., a Delaware corporation (the ?Company?) and CD&R Vector Holdings, L.P., a Cayman Islands exempted limited partnership (the ?M |
|
| March 18, 2021 |
Exhibit 10.13.3 EXECUTION VERSION THIRD AMENDMENT TO AMENDED AND RESTATED STOCKHOLDERS? AGREEMENT This Third Amendment to the Amended and Restated Stockholders? Agreement, dated as of December 31, 2019 (this ?Amendment?), is entered by and between Agilon Health Topco, Inc., a Delaware corporation (the ?Company?) and CD&R Vector Holdings, L.P., a Cayman Islands exempted limited partnership (the ?Ma |
|
| March 18, 2021 |
Exhibit 10.13 EXECUTION VERSION AMENDED AND RESTATED STOCKHOLDERS? AGREEMENT of AGILON HEALTH TOPCO, INC. dated as of November 29, 2019 TABLE OF CONTENTS 1. Definitions 2 2. Shares Subject to Agreement 6 3. Obligations to Vote Voting Shares for Specific Designee 6 4. Obligations to Vote Voting Shares for Removal of Director; Filling Vacancies; No Bad Actor Disqualification 7 5. Transfers by a Stoc |
|
| March 18, 2021 |
Exhibit 10.16.2 Execution Version SECOND AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This Second Amendment, dated as of July 7, 2020 (this ?Amendment?), to the Registration Rights Agreement (as defined below) is entered into by and between Agilon Health Topco, Inc., a Delaware corporation (the ?Company?), and each entity listed on Schedule A to the Agreement (as defined below) (each, an ?Investor? |
|
| March 18, 2021 |
Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT Dated as of February 18, 2021 among AGILON HEALTH, INC., as Borrower AGILON HEALTH INTERMEDIATE HOLDINGS, INC., as Holdings THE LENDERS AND ISSUERS PARTY HERETO, JPMORGAN CHASE BANK, N.A., as Administrative Agent and JPMORGAN CHASE BANK, N.A. BANK OF AMERICA, N.A. WELLS FARGO SECURITIES, LLC DEUTSCHE BANK SECURITIES INC. NOMURA SECURITIES INTERNATION |
|
| March 18, 2021 |
Exhibit 10.2 Confidential EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of May 4, 2020, is entered into by and between Steven J. Sell (the ?Executive?), Agilon Health Topco, Inc., a Delaware corporation (?Parent?), and agilon health, inc., a Delaware corporation and wholly-owned subsidiary of Parent (the ?Company?). W I T N E S S E T H: WHEREAS, Parent and the Company |
|
| March 18, 2021 |
Exhibit 10.4 CONFIDENTIAL EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of December 5, 2019, is entered into by and between Ben Kornitzer (the ?Executive?) and agilon health, inc., a Delaware corporation (the ?Company?) and will be effective as of the Effective Date. W I T N E S S E T H: WHEREAS, the Company desires to employ the Executive as Chief Medi |
|
| March 18, 2021 |
March 18, 2021 Deanna Virginio U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: agilon health, inc. (f/k/a Agilon Health Topco, Inc.) Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted February 10, 2021 CIK No. 0001831097 Dear Ms. Virginio: This letter sets forth the responses of ag |
|
| March 18, 2021 |
Exhibit 10.13.1 EXECUTION VERSION FIRST AMENDMENT TO AMENDED AND RESTATED STOCKHOLDERS? AGREEMENT This First Amendment to the Amended and Restated Stockholders? Agreement, dated as of December 19, 2019 (this ?Amendment?), is entered by and between Agilon Health Topco, Inc., a Delaware corporation (the ?Company?) and CD&R Vector Holdings, L.P., a Cayman Islands exempted limited partnership (the ?Ma |
|
| March 18, 2021 |
Exhibit 10.13.6 EXECUTION VERSION SIXTH AMENDMENT TO AMENDED AND RESTATED STOCKHOLDERS? AGREEMENT This Sixth Amendment to the Amended and Restated Stockholders? Agreement, dated as of March 4, 2020 (this ?Amendment?), is entered by and between Agilon Health Topco, Inc., a Delaware corporation (the ?Company?) and CD&R Vector Holdings, L.P., a Cayman Islands exempted limited partnership (the ?Major |
|
| March 18, 2021 |
Exhibit 10.3 Confidential EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of April 20, 2017, is entered into by and between Lisa Dombro (the ?Executive?), Agilon Health Holdings, Inc., a Delaware corporation (?Parent?), and agilon health, inc., a Delaware corporation and wholly-owned subsidiary of Parent (the ?Company?). W I T N E S S E T H: WHEREAS, Parent and the Comp |
|
| March 18, 2021 |
Exhibit 10.3.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (?Amendment?) is made and entered into effective as of July 1, 2020 (?Effective Date?), and hereby amends the Employment Agreement by and between Lisa Dombro (the ?Executive?), Agilon Health Holdings, Inc., a Delaware corporation (?Parent?), and agilon health, inc., a Delaware corporation and wholly-owned subsidiary of Parent (the ?Co |
|
| March 18, 2021 |
Exhibit 10.16.1 EXECUTION VERSION FIRST AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This First Amendment to the Registration Rights Agreement, dated as of March 4, 2020 (this ?Amendment?), is entered by and among Agilon Health Topco, Inc., a Delaware corporation (the ?Company?), and each entity listed on Schedule A to the Agreement (as defined below) (each, an ?Investor?). WHEREAS, the Company and |
|
| March 18, 2021 |
*Certain identified information has been excluded because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 18, 2021 |
Exhibit 10.16 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), is made as of January 4, 2019, by and among Agilon Health Topco, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?. RECITALS WHEREAS, the Company and the Investors are |
|
| March 18, 2021 |
Exhibit 10.10 Execution Version This CONSULTING AGREEMENT, dated as of July 1, 2016, (this ?Agreement?), is entered into by and among CDR Vector Topco, Inc., a Delaware corporation (the ?Company?), Primary Provider Management Co., Inc., a California corporation (?Opco?), and Clayton, Dubilier & Rice, LLC, a Delaware limited liability company (?CD&R Manager?). W I T N E S S E T H: WHEREAS, CD&R Man |
|
| March 18, 2021 |
EX-10.5 8 d10763dex105.htm EX-10.5 Exhibit 10.5 CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of 01/11/2021 is entered into by and between Timothy Bensley (the “Executive”) and agilon health, inc., a Delaware corporation (the “Company”). W I T N E S S E T H: WHEREAS, Executive is currently employed as Chief Financial Officer of the Company; WHEREAS, in re |
|
| March 18, 2021 |
EX-10.18.1 28 d10763dex10181.htm EX-10.18.1 Exhibit 10.18.1 EXECUTION VERSION FIRST AMENDMENT TO INVESTMENT AGREEMENT This First Amendment, dated as of October 5, 2020 (this “Amendment”), to the Investment Agreement (as defined below) is entered into by and among Agilon Health Topco, Inc., a Delaware corporation (the “Company”), The New Economy Fund (“New Economy”) and SMALLCAP World Fund, Inc. (“ |
|
| March 18, 2021 |
Exhibit 10.8 EXECUTION COPY INDEMNIFICATION AGREEMENT Indemnification Agreement (this ?Agreement?), dated as of December 8, 2020, by and among Agilon Health Topco, Inc., a Delaware corporation (?Topco?), Agilon Health Holdings, Inc. (f/k/a CD&R Vector Topco, Inc.), a Delaware corporation (?Holdings?), agilon health, inc. (f/k/a CD&R Vector Parent, Inc.), a Delaware corporation (?Opco?), and Primar |
|
| March 18, 2021 |
Exhibit 10.9 EXECUTION VERSION INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT, dated as of July 1, 2016 (the ?Agreement?), is among CD&R Vector Topco, Inc., a Delaware corporation (the ?Company?), CD&R Vector Midco, Inc., a Delaware corporation (?Midco?), CD&R Vector Parent, Inc., a Delaware corporation (?Parent?) and Primary Provider Management Co., Inc., a California corporation (?Opco |
|
| March 18, 2021 |
Exhibit 10.13.2 Execution Version SECOND AMENDMENT TO AMENDED AND RESTATED STOCKHOLDERS? AGREEMENT This Second Amendment to the Amended and Restated Stockholders? Agreement, dated as of December 27, 2019 (this ?Amendment?), is entered by and between Agilon Health Topco, Inc., a Delaware corporation (the ?Company?) and CD&R Vector Holdings, L.P., a Cayman Islands exempted limited partnership (the ? |
|
| March 18, 2021 |
Exhibit 10.13.5 EXECUTION VERSION FIFTH AMENDMENT TO AMENDED AND RESTATED STOCKHOLDERS? AGREEMENT This Fifth Amendment to the Amended and Restated Stockholders? Agreement, dated as of February 18, 2020 (this ?Amendment?), is entered by and between Agilon Health Topco, Inc., a Delaware corporation (the ?Company?) and CD&R Vector Holdings, L.P., a Cayman Islands exempted limited partnership (the ?Ma |
|
| February 10, 2021 |
February 10, 2021 Deanna Virginio U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: Agilon Health Topco, Inc. Draft Registration Statement on Form S-1 Submitted December 21, 2020 CIK No. 0001831097 Dear Ms. Virginio: This letter sets forth the responses of Agilon Health Topco, Inc. (the ?Registrant?) t |
|
| February 10, 2021 |
DRS/A 1 filename1.htm Table of Contents Index to Financial Statements As confidentially submitted to the U.S. Securities and Exchange Commission on February 10, 2021, pursuant to the Jumpstart Our Business Startups Act of 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agilon Health |
|
| December 21, 2020 |
DRS 1 filename1.htm Table of Contents Index to Financial Statements As confidentially submitted to the U.S. Securities and Exchange Commission on December 21, 2020, pursuant to the Jumpstart Our Business Startups Act of 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agilon Health To |
|
| December 21, 2020 |
DRSLTR 1 filename1.htm December 21, 2020 CONFIDENTIAL SUBMISSION VIA EDGAR Draft Registration Statement Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: Agilon Health Topco, Inc. Draft Registration Statement on Form S-1 Submitted December 21, 2020 Ladies and Gentlemen: On behalf of our client, Agilon Health Topco, Inc. (the “Comp |
